HRT Benefits, Risks, and Who May Not Be a Candidate

What current guidance actually says

The Menopause Society's 2022 hormone therapy position statement remains the most widely cited synthesis in the U.S. and summarizes the contemporary consensus this way: hormone therapy is the most effective treatment available for vasomotor symptoms and for the genitourinary syndrome of menopause, and it has been shown to reduce the risk of bone loss and fracture. The risks differ by the type of hormone used, the dose, the duration of use, the route of administration, the timing of initiation relative to the final menstrual period, and whether a progestogen is included alongside estrogen. For most healthy women under age 60 or within ten years of menopause, the benefit-risk profile is generally considered favourable.

The U.S. Food and Drug Administration updated the boxed-warning labelling on systemic menopausal hormone therapy products in February 2026, removing several of the broad cardiovascular and breast-cancer risk statements that had been on the labels since 2003 and replacing them with more nuanced language reflecting the subsequent two decades of evidence. The endometrial-cancer warning for unopposed systemic estrogen in women with a uterus was retained — that risk is well-characterised and is the clinical reason a progestogen is required for this population. The change does not mean HRT is risk-free; it means the regulatory communication has been brought closer to the position the menopause societies have held for some time. Your clinician should still walk through the risk picture that applies to you, including any conditions in your personal or family history that change the calculus.

Benefits that are reasonably well established

• Reduction in the frequency and severity of vasomotor symptoms (hot flashes and night sweats).
• Improvement in the vaginal, vulvar, and urinary symptoms of menopause; low-dose vaginal estrogen specifically is highly effective with minimal systemic absorption.
• Reduction in bone loss and in the risk of osteoporotic fracture while therapy is used.
• Improvement in sleep quality for many patients, particularly those whose sleep disruption is driven by night sweats.
• Improvement in mood for some patients, particularly during the perimenopausal transition.

Risks that need to be weighed individually

• Venous thromboembolism (blood clot) risk is increased with oral estrogen and is materially lower with transdermal estrogen.
• Breast cancer risk is modestly increased with combined estrogen-plus-progestin therapy used for several years; risk varies by progestogen type and is not the same with all formulations.
• Stroke risk is small but non-zero with systemic estrogen.
• Endometrial cancer risk is significantly increased by unopposed estrogen in a woman with a uterus, which is why progestogen is required for these patients.
• Gallbladder disease risk is modestly increased with oral estrogen.

Several of these risks are dose-, duration-, and route-dependent in ways that materially change the calculus for an individual patient. This is one of the reasons why clinician judgement matters and why a single one-page summary cannot substitute for it.

Who may not be a candidate

Current guidance generally treats the following as relative or absolute contraindications to systemic hormone therapy; your clinician will weigh the specifics:

• Personal history of breast cancer
• Personal history of estrogen-dependent cancer
• Personal history of venous thromboembolism (DVT or PE)
• Personal history of stroke or coronary artery disease
• Unexplained vaginal bleeding
• Active liver disease
• Known clotting disorder
• Pregnancy

Several of these contraindications apply only to systemic therapy; low-dose vaginal estrogen has a different absorption and safety profile and is used in some patients for whom systemic therapy is not appropriate. The decision belongs with your clinician, not with a checklist.

A note on bioidentical and compounded preparations

“Bioidentical” properly refers to hormones structurally identical to those the body produces — 17-beta-estradiol and micronized progesterone are the canonical examples, and both are available in FDA-approved products. “Compounded bioidentical” refers to preparations mixed by a compounding pharmacy to a clinician's specification. The two are frequently conflated in marketing copy; they are not the same thing. FDA-approved bioidentical products are subject to the same manufacturing and quality-control oversight as any other prescription drug. Compounded preparations are not, and the major menopause societies have stated that compounded bioidentical hormone therapy should be reserved for patients who cannot use an FDA-approved product.

What to do with this

If you want to talk through the risk-benefit picture with a clinician who actually knows this material, find your menopause care options. If you have symptoms but want a structured way to describe them first, use the perimenopause symptoms checklist.